Our Heritage

On the forefront of enhancing cancer patient management through advanced circulating tumor cell (CTC) technology

Since recognizing the potential value of CTCs as a monitoring tool over 2 decades ago, Janssen Diagnostics has been committed to developing innovative technology for obtaining, differentiating, and enumerating CTCs, and to establishing the role of CTCs in predicting prognosis to help inform patient care at any time during the course of disease.